Cosmos Health Highlights Approximately $15 Million Fair Market Value of Real Estate Assets, Exceeding Current Market Capitalization; Evaluates Monetization Options to Address Significant Discount to Book Value
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) highlighted an estimated $15 million fair market value for its wholly owned real estate portfolio in Athens, exceeding its $13.5 million market capitalization as of Feb 17, 2026. Management is evaluating monetization options — sale, JV, or sale-leaseback — to unlock shareholder value.
The two properties are unencumbered, located in Neo Iraklio and Peristeri, and exclude machinery and equipment from the valuation.
Positive
- Real estate value estimated at ~$15M, above market cap
- Properties are wholly owned and unencumbered
- Cana site allows additional buildable capacity subject to approvals
- Proceeds could fund debt reduction or reinvestment
- Strategic locations with strong transport links near Athens airport
Negative
- Market capitalization (~$13.5M) implies a discount to book value
- Monetization outcomes are subject to market conditions and not guaranteed
- Valuation excludes machinery and equipment, so cash proceeds may differ
News Market Reaction – COSM
In the Feb 19 session, COSM declined 5.88%, reflecting a notable negative market reaction. Argus tracked a peak move of +9.4% during that session. Argus tracked a trough of -4.2% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Retail expansion | Positive | +9.5% | C-Scrub added to Superdrug network, broadening UK and Ireland exposure. |
| Feb 18 | Retail expansion | Positive | +9.5% | C-Scrub listing at Tesco, expanding national UK retail footprint. |
| Feb 17 | Brand showcase | Positive | -4.8% | Showcased nutraceutical brands and global distribution discussions at Expo. |
| Feb 11 | Crypto investment | Positive | -2.2% | Expanded digital assets program with additional Bitcoin purchase. |
| Jan 20 | Operations update | Positive | -5.6% | Reported customer growth and robotics expansion supporting added revenue. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Crypto-tag and growth updates often see mixed reactions, with several positive developments met by negative price moves.
Over recent months, Cosmos Health has issued several “crypto” tagged and growth-focused updates, including C-Scrub retail expansion in the UK, showcasing its brand portfolio at World Health Expo Dubai, expanding a digital assets program to $2.5 million, and highlighting operational gains and robotics-enabled capacity supporting $40 million in potential annual revenue. Market reactions have been uneven, with some distribution wins drawing +9.53% moves while operational and crypto-related updates saw declines, underscoring variable sentiment toward these initiatives.
Key Terms
sale leaseback transactions financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today highlighted the intrinsic value of its wholly owned real estate portfolio and announced that it is evaluating strategic monetization options to unlock shareholder value.
Based on independent valuation reports, recent market data, and comparable transactions, management estimates the combined fair market value of the Company’s Cana Laboratories (“Cana”) manufacturing facility and CosmoFarm logistics center at approximately
The estimated value reflects favourable macro conditions in the Greek property market. According to Bank of Greece data, residential property prices in Greece have surpassed their 2008 pre-financial crisis peak and reached record highs. Commercial real estate, including office, retail, and logistics segments, has also experienced sustained pricing and rental growth in key urban centers, particularly in Athens.
The estimated fair market value of the Company’s real estate assets exceeds the Company’s current market capitalization, which stood at approximately
Cana Laboratories – Neo Iraklio, Athens
The Cana property comprises a land plot of approximately 54,000 square feet and a total constructed building area of approximately 35,700 square feet. Based on the applicable building coefficient, the site allows for additional buildable capacity, subject to zoning and regulatory approvals. The property is wholly owned by the Company and is free of any mortgage or other encumbrances.
It is strategically located in Neo Iraklio, a well-established northern suburb of Athens with strong residential density and developed commercial activity. The property offers direct access to Attiki Odos, one of the primary highway arteries serving the greater Athens metropolitan area, and is within a short drive of Athens International Airport, central Athens, and surrounding business districts. It is also located just minutes from The Mall Athens, one of the largest enclosed shopping malls in Greece. Beyond its current pharmaceutical manufacturing and research and development use, the property’s location supports meaningful alternative use potential.
CosmoFarm Logistics Center – Peristeri, Athens
The CosmoFarm facility is wholly owned by the Company, consists of approximately 29,100 square feet, and is located in Peristeri, a densely populated municipality in western Athens with strong infrastructure and transport connectivity. The property currently operates as a pharmaceutical wholesale and distribution hub for Cosmos Health’s logistics subsidiary, CosmoFarm, and incorporates advanced automation and robotic systems supporting inventory management and order execution.
Strategic Optionality
At the current trading levels, the Company’s market capitalization reflects a significant discount to its reported book value (stockholders’ equity) of
Potential alternatives under consideration may include an outright sale, joint venture structures, sale leaseback transactions, or other strategic arrangements, subject to market conditions. Proceeds, if realized, may be used for debt reduction, reinvestment into core growth initiatives, acquisitions, or shareholder value-enhancing actions.
Greg Siokas, CEO of Cosmos Health, stated: “We believe there is a meaningful disconnect between our current valuation and the intrinsic value of our assets, with our real estate assets alone worth more than our entire market capitalization. These strategically located properties provide meaningful financial optionality. As a diversified, vertically integrated pharmaceutical company, we have a clear mission in the healthcare space. If monetizing non-core real estate assets can unlock substantial value, we will evaluate such opportunities carefully and decisively, and act accordingly.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/270cc392-f5ed-4611-a3af-48bc959deccd
https://www.globenewswire.com/NewsRoom/AttachmentNg/50e6cce1-f53a-40ac-8380-2ae0c0cb42a3
